Observational studyMedicine2025
Research and practice on key drug safety monitoring under the normalization of centralized procurement: A case study of 13 selected drugs in a Province.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The National Centralized Volume-Based Procurement policy for drugs has effectively reduced drug prices but has raised concerns regarding quality and safety. To address these issues, adverse drug reactions (ADR) are monitored through a national system. As the policy stabilizes, real-world data (RWD) may improve, making ongoing monitoring crucial for studies and assessments. This study monitored 13 drug types from batches 1 to 8 across 39 provincial hospitals, supplied by 12 marketing authorization holders. We compared tracking data with the "National Adverse Drug Reaction Monitoring System" to analyze reporting rates of ADR and identify risk signals for rational drug use in practice. The monitoring period was from May to December 2023, and routine data from 2019 to 2022 were analyzed using descriptive statistics and comparative methods. A safety evaluation of 13 drug types across 39 hospitals revealed ADR rates ranging from 0 to 4.58% and serious reactions ranging from 0 to 1.97%, with 4 identified risk signals. In comparison, routine monitoring indicated lower rates: 0 to 1.20% for ADR and 0 to 0.80% for serious reactions, with one risk signal. Despite these differences, the ADR risks associated with all drugs were manageable, with no unexpected events exceeding label listings. These findings suggest that the safety of domestic generic drugs is comparable to that of originator drugs, supporting the effectiveness of China's centralized procurement policy. This study aims to enhance coordination among the healthcare, insurance, and pharmaceutical sectors by improving the supervision of drug procurement and RWD research. It emphasizes the need for rigorous monitoring to address safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.